INT3576

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.23
First Reported 1975
Last Reported 1995
Negated 0
Speculated 0
Reported most in Abstract
Documents 6
Total Number 6
Disease Relevance 0
Pain Relevance 2.13

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Sst, Gh1) extracellular region (Sst, Gh1) cytosol (Gh1)
signal transduction (Gh1) mitochondrion (Gh1) plasma membrane (Gh1)
Sst (Rattus norvegicus)
Gh1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Somatostatin 17 100.00 Very High Very High Very High
dexamethasone 5 100.00 Very High Very High Very High
Dopamine 2 100.00 Very High Very High Very High
substance P 1 98.96 Very High Very High Very High
antagonist 4 98.48 Very High Very High Very High
opiate 1 97.28 Very High Very High Very High
Morphine 2 93.24 High High
Dynorphin 10 90.92 High High
agonist 1 90.88 High High
Clonidine 5 90.24 High High

|}

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Somatostatin and TRF similarly inhibit PB-induced GH release.
Somatostatin Negative_regulation (inhibit) of Localization (release) of GH associated with somatostatin
1) Confidence 0.23 Published 1975 Journal Endocrinology Section Abstract Doc Link 810343 Disease Relevance 0 Pain Relevance 0.29
Somatostatin and thyrotropin-releasing factor (TRF) inhibit the in vivo release of GH induced by MS, with 50% inhibition at ca. 2.3 and 4.6 mug/100 g BW, respectively.
Somatostatin Negative_regulation (inhibit) of Localization (release) of GH associated with somatostatin
2) Confidence 0.23 Published 1975 Journal Endocrinology Section Abstract Doc Link 810343 Disease Relevance 0 Pain Relevance 0.27
Glucocorticoids are known to inhibit GH secretion via somatostatin.
somatostatin Negative_regulation (inhibit) of Localization (secretion) of GH associated with somatostatin
3) Confidence 0.14 Published 1995 Journal Endocr. Res. Section Abstract Doc Link 8582323 Disease Relevance 0 Pain Relevance 0.40
Somatostatin, dopamine, T3, dexamethasone, and 5 alpha-dihydrotestosterone were used to inhibit the secretion of GH, PRL, TSH, ACTH/beta-endorphin, or LH/FSH, respectively.
Somatostatin Negative_regulation (inhibit) of Localization (secretion) of GH associated with dopamine, somatostatin and dexamethasone
4) Confidence 0.10 Published 1987 Journal Endocrinology Section Abstract Doc Link 2885174 Disease Relevance 0 Pain Relevance 0.55
GH release induced by L-692,429 was inhibited by somatostatin as well as by GHRP-6 and substance P antagonists but not by GRF or opiate antagonists.
somatostatin Negative_regulation (inhibited) of Localization (release) of GH associated with antagonist, somatostatin, opiate and substance p
5) Confidence 0.07 Published 1993 Journal Horm. Res. Section Abstract Doc Link 7905455 Disease Relevance 0 Pain Relevance 0.29
GH release induced by hpGHRH-(1-44) was blocked by somatostatin (IC50, approximately 10 nM) without affecting hpGHRH-(1-44)-induced release of Dyn A1-13-IR.
somatostatin Negative_regulation (blocked) of Localization (release) of GH associated with somatostatin
6) Confidence 0.01 Published 1987 Journal Endocrinology Section Abstract Doc Link 2879724 Disease Relevance 0 Pain Relevance 0.32

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox